ArticleAntimicrobial agents and chemotherapy2009
Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- RACK1 mediates rewiring of intracellular networks induced by hepatitis C virus infection.PLoS pathogens · 2019Article
- Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach.Journal of virology · 2015Article
- Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.Journal of virology · 2014Article
- Identification of 23-(s)-2-amino-3-phenylpropanoyl-silybin as an antiviral agent for influenza A virus infection in vitro and in vivo.Antimicrobial agents and chemotherapy · 2013Article
- Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food Supplements.Antioxidants (Basel, Switzerland) · 2013Article
- Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay.Antimicrobial agents and chemotherapy · 2012Article
- New hepatitis C virus drug discovery strategies and model systems.Expert opinion on drug discovery · 2012Review
- Fluorescence resonance energy transfer-based intracellular assay for the conformation of hepatitis C virus drug target NS5A.Journal of virology · 2012Article
- Article
- High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.PloS one · 2012Article
- Biology in a gray box: targeting the emergent properties of protein complexes: 2011 Yale Chemical Biology Symposium.The Yale journal of biology and medicine · 2011Review
- Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?Hepatology (Baltimore, Md.) · 2010Article
- Potential treatment options and future research to increase hepatitis C virus treatment response rate.Hepatic medicine : evidence and research · 2010Article
- A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.PLoS pathogens · 2010Article
- Hepatitis C virus experimental model systems and antiviral drug research.Virologica Sinica · 2010Review
- Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.Current protocols in microbiology · 2010Article
- A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A major obstacle in the treatment of chronic hepatitis C virus (HCV) infection has been the lack of effective, well-tolerated therapeutics. Notably, the recent development of the HCV cell culture infection system now allows not only for the study of the entire viral life cycle, but also for the screening of inhibitors against all aspects of HCV infection. However, in order to screen libraries of potential antiviral compounds, it is necessary to develop a highly reproducible, accurate assay for HCV infection adaptable for high-throughput screening (HTS) automation. Using an internally quenched 5-FAM/QXL 520 fluorescence resonance energy transfer (FRET) substrate containing the HCV NS3 peptide cleavage sequence, we report the development of a simple, mix-and-measure, homogenous, cell-based HCV infection assay amendable for HTS. This assay makes use of synchronized, nondividing human hepatoma-derived Huh7 cells, which support more-reproducible long-term HCV infection and can be readily scaled down to a 96-well-plate format. We demonstrate that this stable cell culture method eliminates common problems associated with standard cell-based HTS, such as cell culture variability, poor reproducibility, and low signal intensity. Importantly, this HCV FRET assay not only can identify inhibitors that act throughout the viral life cycle as effectively as more-standard HCV assays, such as real-time quantitative PCR and Western blot analysis, but also exhibits a high degree of accuracy with limited signal variation (i.e., Z' > or = 0.6), providing the basis for a robust HTS campaign for screening compound libraries and identifying novel HCV antivirals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.